RU2000102889A - APPLICATION OF KOLKHINOL DERIVATIVES AS A MEANS DAMAGING VESSELS - Google Patents
APPLICATION OF KOLKHINOL DERIVATIVES AS A MEANS DAMAGING VESSELSInfo
- Publication number
- RU2000102889A RU2000102889A RU2000102889/14A RU2000102889A RU2000102889A RU 2000102889 A RU2000102889 A RU 2000102889A RU 2000102889/14 A RU2000102889/14 A RU 2000102889/14A RU 2000102889 A RU2000102889 A RU 2000102889A RU 2000102889 A RU2000102889 A RU 2000102889A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- cycloalkyl
- independently
- use according
- alkynyl
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 125000004442 acylamino group Chemical group 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 3
- 150000004677 hydrates Chemical class 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- -1 acetylamino, acetylmethylamino, amino, methylamino Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- LOTBYPQQWICYBB-UHFFFAOYSA-N methyl n-hexyl-n-[2-(hexylamino)ethyl]carbamate Chemical group CCCCCCNCCN(C(=O)OC)CCCCCC LOTBYPQQWICYBB-UHFFFAOYSA-N 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Claims (12)
где R1, R2, R3 и R6 независимо представляют Н, необязательно замещенный алкил, циклоалкил, алкенил, алкинил, аралкил, алканоил, РО3Н2;
X представляет карбонил (СО), тиокарбонил (CS), метилен (СН2) или группу CHR4;
R4 представляет ОН, О-алкил или NR8R9;
R5 и R7 независимо представляют Н, алкил, галоген, гидрокси, алкокси, нитро- или аминогруппу;
R8 представляет Н, необязательно замещенный алкил, циклоалкил, алканоил, тиоалканоил, арил, гетероарил, арилкарбонил, гетероарилкарбонил, алкоксикарбонил, арилоксикарбонил, аминокарбонил, алкиламинокарбонил, диалкиламинокарбонил, ариламинокарбонил, алкилсульфонил, арилсульфонил, аминосульфонил, алкиламиносульфонил, диалкиламиносульфонил или ариламиносульфонил;
R9 представляет Н, алкил или циклоалкил;
и их фармацевтически приемлемых солей, сольватов и гидратов.l. The use of colquinol derivatives to obtain compositions for the treatment of diseases affecting the process of vascular formation, where the colhinol derivative has the formula
where R 1 , R 2 , R 3 and R 6 independently represent H, optionally substituted alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, alkanoyl, PO 3 H 2 ;
X is carbonyl (CO), thiocarbonyl (CS), methylene (CH 2 ) or CHR 4 group;
R 4 is OH, O-alkyl or NR 8 R 9 ;
R 5 and R 7 are independently H, alkyl, halogen, hydroxy, alkoxy, nitro, or amino;
R 8 is an H 2 O 2
R 9 is H, alkyl or cycloalkyl;
and their pharmaceutically acceptable salts, solvates and hydrates.
где R1, R2 и R3 независимо представляют H, необязательно замощенный алкил, циклоалкил, алкенил, алкинил, алканоил или РО3Н2;
R6 представляет РО3Н2;
R4 представляет Н или NR8R9;
R5 и R7 независимо представляют Н, алкил, галоген, алкокси-, нитро- или аминогруппу;
R8 представляет Н, необязательно замещенный алкил, циклоалкил, алканоил, тиоалканоил, арил, гетероарил, арилкарбонил, гетероарилкарбонил, алкоксикарбонил, арилоксикарбонил, аминокарбонил, алкиламинокарбонил, диaлкилaминoкapбoнил, ариламинокарбонил, алкилсульфонил, арилсульфонил, аминосульфонил, алкиламиносульфонил, диалкиламиносульфонил или ариламиносульфонил;
и R9 представляет Н, алкил или циклоалкил,
и его фармацевтически приемлемые соли, сольваты и гидраты.10. The compound according to claim 7 of the formula
where R 1 , R 2 and R 3 independently represent H, optionally tiled alkyl, cycloalkyl, alkenyl, alkynyl, alkanoyl or PO 3 H 2 ;
R 6 is PO 3 H 2 ;
R 4 is H or NR 8 R 9 ;
R 5 and R 7 are independently H, alkyl, halogen, alkoxy, nitro or amino;
R 8 is a halogen free
and R 9 is H, alkyl or cycloalkyl,
and its pharmaceutically acceptable salts, solvates and hydrates.
где R1, R2 и R3 независимо представляют Н, необязательно замещенный алкил, циклоалкил, алкенил, алкинил, алканоил или РО3Н2;
R6 представляет Н, необязательно замещенный алкил, циклоалкил, алкенил, алкинил или РО3Н2;
R4 представляет Н или NR8R9;
R5 и R7 независимо представляют Н, аклил, галоген, нитро- или аминогруппу;
R8 представляет Н, необязательно замещенный алкил, циклоалкил, алканоил, тиоалканоил, арил, гетероарил, арилкарбонил, гетероарилкарбонил, алкоксикарбонил, арилоксикарбонил, аминокарбонил, алкиламинокарбонил, диалкиламинокарбонил, ариламинокарбонил, алкил сульфонил, арилсульфонил, аминосульфонил, алкиламиносульфонил, диалкиламиносульфонил или ариламиносульфонил;
и R9 представляет Н, алкил или циклоалкил при условии, что когда R1, R2 и R3 все представляют метильные группы и R4представляет водород, ацетиламино-, ацетилметиламино-, амино, метиламино- или диметиламиногруппу, тогда R6 не является водородом, метилом, гидроксиэтилом или ацетоксиэтилом,
и его фармацевтически приемлемые соли, сольваты и гидраты.11. The compound of the formula
where R 1 , R 2 and R 3 independently represent H, optionally substituted alkyl, cycloalkyl, alkenyl, alkynyl, alkanoyl or PO 3 H 2 ;
R 6 is H, optionally substituted alkyl, cycloalkyl, alkenyl, alkynyl or PO 3 H 2 ;
R 4 is H or NR 8 R 9 ;
R 5 and R 7 are independently H, alkyl, halogen, nitro or amino;
R 8 is an option for an ally
and R 9 is H, alkyl or cycloalkyl, provided that when R 1 , R 2 and R 3 are all methyl groups and R 4 is hydrogen, acetylamino, acetylmethylamino, amino, methylamino or dimethylamino, then R 6 is not hydrogen, stands, hydroxyethyl or acetoxyethyl,
and its pharmaceutically acceptable salts, solvates and hydrates.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9714249.1 | 1997-07-08 | ||
| GBGB9714249.1A GB9714249D0 (en) | 1997-07-08 | 1997-07-08 | Vascular damaging agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2000102889A true RU2000102889A (en) | 2001-10-27 |
| RU2232021C2 RU2232021C2 (en) | 2004-07-10 |
Family
ID=10815450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2000102889/15A RU2232021C2 (en) | 1997-07-08 | 1998-07-06 | Application of colchinol derivatives as agents impairing vessels |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US6423753B1 (en) |
| EP (1) | EP1001785B1 (en) |
| JP (1) | JP3455549B2 (en) |
| KR (1) | KR100655808B1 (en) |
| CN (1) | CN1181825C (en) |
| AT (1) | ATE334684T1 (en) |
| AU (1) | AU741213B2 (en) |
| BR (1) | BR9810681A (en) |
| CA (1) | CA2292549C (en) |
| CZ (1) | CZ296018B6 (en) |
| DE (1) | DE69835434T2 (en) |
| ES (1) | ES2270524T3 (en) |
| GB (1) | GB9714249D0 (en) |
| HU (1) | HUP0002493A3 (en) |
| ID (1) | ID25483A (en) |
| IL (1) | IL133899A0 (en) |
| NO (2) | NO321621B1 (en) |
| NZ (1) | NZ501341A (en) |
| PL (1) | PL337926A1 (en) |
| RU (1) | RU2232021C2 (en) |
| SK (1) | SK132000A3 (en) |
| TR (1) | TR199903149T2 (en) |
| UA (1) | UA72731C2 (en) |
| WO (1) | WO1999002166A1 (en) |
Families Citing this family (376)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9900334D0 (en) * | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| MXPA01008182A (en) | 1999-02-10 | 2003-08-20 | Astrazeneca Ab | Quinazoline derivatives as angiogenesis inhibitors. |
| SE9903544D0 (en) | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
| GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| RU2268729C2 (en) * | 2000-03-31 | 2006-01-27 | Энджиоджен Фармасьютикалз Лтд. | Combined therapies using of angiogenesis damaging activity |
| CN1422157A (en) * | 2000-03-31 | 2003-06-04 | 安吉奥金尼药品有限公司 | Fractionated dose therapy utilizing vasodisruptive activity |
| EE200200565A (en) * | 2000-03-31 | 2004-06-15 | Angiogene Pharmaceuticals Ltd. | Combination therapy with vascular adverse effects |
| EP1289952A1 (en) * | 2000-05-31 | 2003-03-12 | AstraZeneca AB | Indole derivatives with vascular damaging activity |
| AR028948A1 (en) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | NEW COMPOUNDS |
| CA2411160A1 (en) * | 2000-07-07 | 2002-01-17 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as vascular damaging agents |
| MXPA02012903A (en) * | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors. |
| US6720323B2 (en) | 2000-07-07 | 2004-04-13 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
| SE0003828D0 (en) | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Novel compounds |
| US20040229960A1 (en) * | 2001-07-13 | 2004-11-18 | David Sherris | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| EP1438281A4 (en) | 2001-10-26 | 2006-04-26 | Oxigene Inc | FUNCTIONALIZED STYLENE DERIVATIVES AS IMPROVED MEDIUM-TERM MEDICAL DEVICES |
| US7268230B2 (en) | 2002-02-01 | 2007-09-11 | Astrazeneca Ab | Quinazoline compounds |
| AU2003216558B2 (en) * | 2002-04-16 | 2008-05-29 | Astrazeneca Ab | Combination therapy for the treatment of cancer |
| GB0217431D0 (en) | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
| US7482355B2 (en) | 2002-08-24 | 2009-01-27 | Astrazeneca Ab | Pyrimidine derivatives as modulators of chemokine receptor activity |
| GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| GB0223379D0 (en) * | 2002-10-09 | 2002-11-13 | Angiogene Pharm Ltd | Combination therapy |
| FR2848212B1 (en) * | 2002-12-06 | 2006-10-27 | Aventis Pharma Sa | COLCHICINE DERIVATIVES, PREPARATION METHOD, PRODUCTS OBTAINED BY THIS PROCESS AND USE |
| PL221490B1 (en) | 2002-12-24 | 2016-04-29 | Astrazeneca Ab | Phosphonooxy quinazoline derivatives and their pharmaceutical use |
| US7655646B2 (en) * | 2003-01-21 | 2010-02-02 | Thallion Pharmaceuticals, Inc. | Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals |
| EP1601348A4 (en) | 2003-02-28 | 2008-12-10 | Oxigene Inc | Compositions and methods with enhanced therapeutic activity |
| SE0301010D0 (en) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| SE0301569D0 (en) | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
| BRPI0411567A (en) * | 2003-06-18 | 2006-08-01 | Angiogene Pharm Ltd | use of zd6126 or a pharmaceutically acceptable salt thereof and one of 5-fu, cpt-11, and 5-fu and cpt-11, pharmaceutical composition, kit, and methods for producing a vascular damage effect in an animal of warm blood and for the treatment of a cancer involving a solid tumor in a warm blooded animal |
| GB0316123D0 (en) * | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
| GB0318422D0 (en) | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| EP2251327B1 (en) | 2003-11-19 | 2014-02-12 | Array Biopharma, Inc. | Heterocyclic inhibitors of mek |
| GB0328243D0 (en) | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Methods |
| GB0329771D0 (en) * | 2003-12-23 | 2004-01-28 | Angiogene Pharm Ltd | Chemical processes & intermediates |
| WO2005066163A2 (en) | 2004-01-05 | 2005-07-21 | Astrazeneca Ab | Thiophene derivatives as chk 1 inihibitors |
| SE0401657D0 (en) | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | Chemical compounds |
| GB0415320D0 (en) | 2004-07-08 | 2004-08-11 | Astrazeneca Ab | Novel compounds |
| RS53145B (en) | 2004-08-28 | 2014-06-30 | Astrazeneca Ab. | PIRIMIDINE SULFONAMIDE DERIVATIVES AS CHEMOKIN RECEPTOR MODULATORS |
| CN105085678B (en) | 2004-12-21 | 2019-05-07 | 阿斯利康公司 | Angiopoietin-2 antibody and its application |
| ES2555063T3 (en) | 2005-02-04 | 2015-12-28 | Astrazeneca Ab | Pyrazolilaminopyridine derivatives useful as kinase inhibitors |
| EP2361905B1 (en) | 2005-05-18 | 2013-03-06 | Array Biopharma Inc. | Heterocyclic Inhibitors of MEK and methods of use thereof |
| WO2007011293A1 (en) | 2005-07-21 | 2007-01-25 | Astrazeneca Ab | Novel piperidine derivatives |
| TW200738634A (en) | 2005-08-02 | 2007-10-16 | Astrazeneca Ab | New salt |
| TW200738658A (en) | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| JPWO2007034917A1 (en) | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | New adenine compounds |
| JPWO2007034882A1 (en) | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | New adenine compounds |
| WO2007034881A1 (en) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | Novel adenine compound |
| JPWO2007034817A1 (en) | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | New adenine compounds |
| US20090099216A1 (en) | 2005-09-22 | 2009-04-16 | Astrazeneca Aktiebolag A Corporation Of Sweden | Novel adenine compound |
| US7384935B2 (en) * | 2005-09-27 | 2008-06-10 | Thallion Pharmaceuticals, Inc. | Phosphate prodrugs of a farnesyl dibenzodiazepinone, processes for their production and their use as pharmaceuticals |
| WO2007039736A1 (en) | 2005-10-06 | 2007-04-12 | Astrazeneca Ab | Novel compounds |
| RU2463302C2 (en) | 2005-10-28 | 2012-10-10 | Астразенека Аб | 4-(3-aminopyrazole)pyrimidine applicable as tyrosine kinase inhibitors for treating malignant growth |
| CN101356171A (en) | 2005-11-15 | 2009-01-28 | 阿雷生物药品公司 | N4-phenyl-quinazolin-4-amine derivatives and related compounds as ERBBI type receptor tyrosine kinase inhibitors for the treatment of proliferative diseases |
| TW200730512A (en) | 2005-12-12 | 2007-08-16 | Astrazeneca Ab | Novel compounds |
| ES2385054T3 (en) | 2005-12-13 | 2012-07-17 | Medimmune Limited | Specific binding proteins for insulin-like growth factors and uses thereof |
| US20080293775A1 (en) | 2005-12-15 | 2008-11-27 | Astrazeneca Ab | Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease |
| TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
| CN101454284A (en) | 2006-05-26 | 2009-06-10 | 阿斯利康(瑞典)有限公司 | Biaryl or aryl-heteroaryl substituted indoles |
| CL2007002225A1 (en) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A |
| DE102006037478A1 (en) | 2006-08-10 | 2008-02-14 | Merck Patent Gmbh | 2- (Heterocyclylbenzyl) -pyridazinone derivatives |
| NZ575672A (en) | 2006-08-23 | 2011-10-28 | Kudos Pharm Ltd | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors |
| TW200825084A (en) | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
| TW200831528A (en) | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
| WO2008075005A1 (en) | 2006-12-19 | 2008-06-26 | Astrazeneca Ab | Quinuclidinol derivatives as muscarinic receptor antagonists |
| CL2008000191A1 (en) | 2007-01-25 | 2008-08-22 | Astrazeneca Ab | COMPOUNDS DERIVED FROM 4-AMINO-CINNOTINA-3-CARBOXAMIDA; CSF-1R QUINASA INHIBITORS; YOUR PREPARATION PROCESS; AND ITS USE TO TREAT CANCER. |
| JPWO2008114819A1 (en) | 2007-03-20 | 2010-07-08 | 大日本住友製薬株式会社 | New adenine compounds |
| PE20081887A1 (en) | 2007-03-20 | 2009-01-16 | Dainippon Sumitomo Pharma Co | NEW ADENINE COMPOUND |
| UA99459C2 (en) | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
| DE102007025717A1 (en) | 2007-06-01 | 2008-12-11 | Merck Patent Gmbh | Aryl ether pyridazinone derivatives |
| DE102007025718A1 (en) | 2007-06-01 | 2008-12-04 | Merck Patent Gmbh | pyridazinone derivatives |
| DE102007026341A1 (en) | 2007-06-06 | 2008-12-11 | Merck Patent Gmbh | Benzoxazolonderivate |
| UA100983C2 (en) | 2007-07-05 | 2013-02-25 | Астразенека Аб | Biphenyloxypropanoic acid as crth2 modulator and intermediates |
| DE102007032507A1 (en) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | pyridazinone derivatives |
| DE102007038957A1 (en) | 2007-08-17 | 2009-02-19 | Merck Patent Gmbh | 6-thioxo-pyridazine derivatives |
| DE102007041115A1 (en) | 2007-08-30 | 2009-03-05 | Merck Patent Gmbh | Thiadiazinonderivate |
| WO2009044200A1 (en) | 2007-10-04 | 2009-04-09 | Astrazeneca Ab | Steroidal [3, 2-c] pyrazole compounds, with glucocorticoid activity |
| JP4705695B2 (en) | 2007-10-11 | 2011-06-22 | アストラゼネカ アクチボラグ | Pyrrolo [2,3-D] pyrimidine derivatives as protein kinase B inhibitors |
| US20090192098A1 (en) | 2007-11-21 | 2009-07-30 | Oxigene, Inc. | Method for treating hematopoietic neoplasms |
| DE102007061963A1 (en) | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | pyridazinone derivatives |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| EP2245064B1 (en) | 2007-12-21 | 2014-07-23 | Medimmune Limited | BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Ralpha) |
| ES2394547T3 (en) | 2008-02-06 | 2013-02-01 | Astrazeneca Ab | Compounds |
| EP2254889B1 (en) | 2008-02-28 | 2012-12-19 | Merck Patent GmbH | Protein kinase inhibitors and use thereof |
| DE102008019907A1 (en) | 2008-04-21 | 2009-10-22 | Merck Patent Gmbh | pyridazinone derivatives |
| AU2009252938B2 (en) | 2008-05-27 | 2012-04-26 | Astrazeneca Ab | Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states |
| DE102008025750A1 (en) | 2008-05-29 | 2009-12-03 | Merck Patent Gmbh | Dihydropyrazolderivate |
| DE102008028905A1 (en) | 2008-06-18 | 2009-12-24 | Merck Patent Gmbh | 3- (3-pyrimidin-2-yl-benzyl) - [1,2,4] triazolo [4,3-b] pyridazine derivatives |
| DE102008029734A1 (en) | 2008-06-23 | 2009-12-24 | Merck Patent Gmbh | Thiazolyl-piperidine derivatives |
| TWI461423B (en) | 2008-07-02 | 2014-11-21 | Astrazeneca Ab | Thiazolidinedione compounds useful in the treatment of pim kinase related conditions and diseases |
| DE102008037790A1 (en) | 2008-08-14 | 2010-02-18 | Merck Patent Gmbh | Bicyclic triazole derivatives |
| DE102008038221A1 (en) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | 7-azaindole derivatives |
| CA2735900A1 (en) | 2008-09-19 | 2010-03-25 | Medimmune, Llc | Antibodies directed to dll4 and uses thereof |
| DE102008052943A1 (en) | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | azaindole derivatives |
| WO2010067102A1 (en) | 2008-12-09 | 2010-06-17 | Astrazeneca Ab | Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders |
| CA2746652C (en) | 2008-12-11 | 2018-03-06 | Axcentua Pharmaceuticals Ab | Crystalline forms of genistein |
| US7863325B2 (en) | 2008-12-11 | 2011-01-04 | Axcentua Pharmaceuticals Ab | Crystalline genistein sodium salt dihydrate |
| US20100152197A1 (en) | 2008-12-15 | 2010-06-17 | Astrazeneca Ab | (4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives |
| AU2009333653B2 (en) | 2008-12-17 | 2015-09-10 | Merck Patent Gmbh | C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof |
| ES2603208T3 (en) | 2008-12-18 | 2017-02-24 | Merck Patent Gmbh | Tricyclic azaindoles |
| DE102008063667A1 (en) | 2008-12-18 | 2010-07-01 | Merck Patent Gmbh | 3- (3-pyrimidin-2-yl-benzyl) - ° [1,2,4] triazolo [4,3-b] pyrimidine derivatives |
| US20110053923A1 (en) | 2008-12-22 | 2011-03-03 | Astrazeneca | Chemical compounds 610 |
| EP2379595A2 (en) | 2008-12-23 | 2011-10-26 | AstraZeneca AB | Targeted binding agents directed to 5 1 and uses thereof |
| DE102008062825A1 (en) | 2008-12-23 | 2010-06-24 | Merck Patent Gmbh | 3- (3-pyrimidin-2-yl-benzyl) - [1,2,4] triazolo [4,3-b] pyridazine derivatives |
| DE102008062826A1 (en) | 2008-12-23 | 2010-07-01 | Merck Patent Gmbh | pyridazinone derivatives |
| DE102009003954A1 (en) | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | pyridazinone derivatives |
| DE102009003975A1 (en) | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Benzothiazolonderivate |
| DE102009004061A1 (en) | 2009-01-08 | 2010-07-15 | Merck Patent Gmbh | pyridazinone derivatives |
| WO2010089580A1 (en) | 2009-02-06 | 2010-08-12 | Astrazeneca Ab | Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4 |
| CN102388048B (en) | 2009-02-10 | 2014-07-30 | 阿斯利康(瑞典)有限公司 | Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer |
| ES2529205T3 (en) | 2009-03-13 | 2015-02-17 | Cellzome Limited | Pyrimidine derivatives as mTOR inhibitors |
| GB0905127D0 (en) | 2009-03-25 | 2009-05-06 | Pharminox Ltd | Novel prodrugs |
| UY32520A (en) | 2009-04-03 | 2010-10-29 | Astrazeneca Ab | COMPOUNDS THAT HAVE AGONIST ACTIVITY OF THE GLUCOCORTICOESTEROID RECEPTOR |
| CA2758614A1 (en) | 2009-04-14 | 2010-10-21 | Cellzome Limited | Fluoro substituted pyrimidine compounds as jak3 inhibitors |
| US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
| US20100317593A1 (en) | 2009-06-12 | 2010-12-16 | Astrazeneca Ab | 2,3-dihydro-1h-indene compounds |
| GB0913342D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | Compounds - 801 |
| US20120172385A1 (en) | 2009-09-11 | 2012-07-05 | Richard John Harrison | Ortho substituted pyrimidine compounds as jak inhibitors |
| DE102009043260A1 (en) | 2009-09-28 | 2011-04-28 | Merck Patent Gmbh | Pyridinyl-imidazolone derivatives |
| RU2012116877A (en) | 2009-10-02 | 2013-11-10 | Астразенека Аб | COMPOUNDS OF 2-PYRIDONE USED AS NEUTROPHIL ELASTASE INHIBITORS |
| DE102009049679A1 (en) | 2009-10-19 | 2011-04-21 | Merck Patent Gmbh | Pyrazolopyrimidinderivate |
| MX2012004020A (en) | 2009-10-20 | 2012-05-08 | Cellzome Ltd | Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors. |
| WO2011048409A1 (en) | 2009-10-20 | 2011-04-28 | Astrazeneca Ab | Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| US8399460B2 (en) | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
| AU2010322478B2 (en) | 2009-11-18 | 2013-11-14 | Glaxosmithkline Intellectual Property (No. 3) Limited | Benzoimidazole compounds and uses thereof |
| CA2778714C (en) | 2009-11-24 | 2018-02-27 | Medimmune Limited | Targeted binding agents against b7-h1 |
| WO2011068233A1 (en) | 2009-12-03 | 2011-06-09 | Dainippon Sumitomo Pharma Co., Ltd. | Imidazoquinolines which act via toll - like receptors (tlr) |
| DE102009058280A1 (en) | 2009-12-14 | 2011-06-16 | Merck Patent Gmbh | thiazole |
| BR112012014164A2 (en) | 2009-12-14 | 2016-05-17 | Merck Patent Gmbh | sphingosine kinase inhibitors |
| CN102639513A (en) | 2009-12-17 | 2012-08-15 | 默克专利有限公司 | Sphingosine kinase inhibitors |
| AU2011206864B2 (en) | 2010-01-15 | 2013-12-19 | Suzhou Neupharma Co., Ltd. | Certain chemical entities, compositions, and methods |
| WO2011089416A1 (en) | 2010-01-19 | 2011-07-28 | Astrazeneca Ab | Pyrazine derivatives |
| WO2011095807A1 (en) | 2010-02-07 | 2011-08-11 | Astrazeneca Ab | Combinations of mek and hh inhibitors |
| EP2542536B1 (en) | 2010-03-04 | 2015-01-21 | Cellzome Limited | Morpholino substituted urea derivatives as mtor inhibitors |
| WO2011114148A1 (en) | 2010-03-17 | 2011-09-22 | Astrazeneca Ab | 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists |
| US20130131043A1 (en) | 2010-04-30 | 2013-05-23 | Richard John Harrison | Pyrazole compounds as jak inhibitors |
| US20130059916A1 (en) | 2010-05-26 | 2013-03-07 | Stephane Rocchi | Biguanide compounds and its use for treating cancer |
| CA2799653A1 (en) | 2010-06-04 | 2011-12-08 | Bertrand Leblond | Substituted isoquinolines and their use as tubulin polymerization inhibitors |
| WO2011154677A1 (en) | 2010-06-09 | 2011-12-15 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760 |
| GB201009801D0 (en) | 2010-06-11 | 2010-07-21 | Astrazeneca Ab | Compounds 950 |
| SA111320519B1 (en) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | Pyrimidinyl compounds for use as ATR inhibitors |
| EP2588105A1 (en) | 2010-07-01 | 2013-05-08 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
| TW201219383A (en) | 2010-08-02 | 2012-05-16 | Astrazeneca Ab | Chemical compounds |
| TWI535712B (en) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | Chemical compounds |
| DE102010034699A1 (en) | 2010-08-18 | 2012-02-23 | Merck Patent Gmbh | pyrimidine derivatives |
| US9040545B2 (en) | 2010-08-20 | 2015-05-26 | Cellzome Limited | Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors |
| US9018197B2 (en) | 2010-08-28 | 2015-04-28 | Suzhou Neupharma Co. Ltd. | Tetradecahydro-1H-cyclopenta[a]phenanthrene compounds, compositions, and related methods of use |
| GB201016442D0 (en) | 2010-09-30 | 2010-11-17 | Pharminox Ltd | Novel acridine derivatives |
| DE102010048800A1 (en) | 2010-10-20 | 2012-05-10 | Merck Patent Gmbh | quinoxaline |
| DE102010049595A1 (en) | 2010-10-26 | 2012-04-26 | Merck Patent Gmbh | quinazoline derivatives |
| WO2012062704A1 (en) | 2010-11-09 | 2012-05-18 | Cellzome Limited | Pyridine compounds and aza analogues thereof as tyk2 inhibitors |
| WO2012067269A1 (en) | 2010-11-19 | 2012-05-24 | Dainippon Sumitomo Pharma Co., Ltd. | Aminoalkoxyphenyl compounds and their use in the treatment of disease |
| JP2013542916A (en) | 2010-11-19 | 2013-11-28 | 大日本住友製薬株式会社 | Cyclic amide compounds and their use in the treatment of diseases |
| WO2012066335A1 (en) | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Phenol compounds als toll -like receptor 7 agonists |
| WO2012066336A1 (en) | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Benzylamine compounds as toll -like receptor 7 agonists |
| ES2575688T3 (en) | 2010-12-16 | 2016-06-30 | Sumitomo Dainippon Pharma Co., Ltd. | Imidazo [4,5-c] quinolin-1-yl derivative useful in therapy |
| US8895570B2 (en) | 2010-12-17 | 2014-11-25 | Astrazeneca Ab | Purine derivatives |
| RU2013133846A (en) | 2010-12-20 | 2015-01-27 | Медиммьюн Лимитед | ANTIBODIES AGAINST IL-18 AND THEIR APPLICATION |
| WO2012103810A1 (en) | 2011-02-02 | 2012-08-09 | Suzhou Neupharma Co., Ltd | Certain chemical entities, compositions, and methods |
| CA2827172C (en) | 2011-02-17 | 2019-02-26 | Cancer Therapeutics Crc Pty Limited | Selective fak inhibitors |
| WO2012110773A1 (en) | 2011-02-17 | 2012-08-23 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| EP2694511A1 (en) | 2011-04-04 | 2014-02-12 | Cellzome Limited | Dihydropyrrolo pyrimidine derivatives as mtor inhibitors |
| US8530470B2 (en) | 2011-04-13 | 2013-09-10 | Astrazeneca Ab | Chromenone derivatives |
| WO2012143320A1 (en) | 2011-04-18 | 2012-10-26 | Cellzome Limited | (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors |
| WO2012175991A1 (en) | 2011-06-24 | 2012-12-27 | Pharminox Limited | Fused pentacyclic anti - proliferative compounds |
| US20140227293A1 (en) | 2011-06-30 | 2014-08-14 | Trustees Of Boston University | Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1) |
| MX353334B (en) | 2011-07-12 | 2018-01-09 | Astrazeneca Ab | N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator. |
| JP5427321B2 (en) | 2011-07-27 | 2014-02-26 | アストラゼネカ アクチボラグ | 2- (2,4,5-substituted-anilino) pyrimidine compounds |
| WO2013014162A1 (en) | 2011-07-28 | 2013-01-31 | Cellzome Limited | Heterocyclyl pyrimidine analogues as jak inhibitors |
| WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| WO2013017479A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| DE102011111400A1 (en) | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclic heteroaromatic compounds |
| CN107245056A (en) | 2011-08-26 | 2017-10-13 | 润新生物公司 | Chemical entities, composition and method |
| WO2013033250A1 (en) | 2011-09-01 | 2013-03-07 | Xiangping Qian | Certain chemical entities, compositions, and methods |
| US9518029B2 (en) | 2011-09-14 | 2016-12-13 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| AU2012311504B2 (en) | 2011-09-20 | 2016-03-24 | Cellzome Limited | Pyrazolo[4,3-C]pyridine derivatives as kinase inhibitors |
| BR112014006743A8 (en) | 2011-09-21 | 2018-01-09 | Cellzome Ltd | compound, use of a compound, and method for treating, controlling, retarding or preventing one or more conditions |
| EP2757885B1 (en) | 2011-09-21 | 2017-03-15 | Neupharma, Inc. | Certain chemical entites, compositions, and methods |
| EP2760458B1 (en) | 2011-09-29 | 2017-06-14 | The University of Liverpool | Prevention and/or treatment of cancer and/or cancer metastasis |
| WO2013049701A1 (en) | 2011-09-30 | 2013-04-04 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| US9242993B2 (en) | 2011-10-07 | 2016-01-26 | Cellzome Limited | Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors |
| US20130178520A1 (en) | 2011-12-23 | 2013-07-11 | Duke University | Methods of treatment using arylcyclopropylamine compounds |
| CN104169272A (en) | 2011-12-23 | 2014-11-26 | 赛尔佐姆有限公司 | Pyrimidine-2,4-diamine derivatives as kinase inhibitors |
| US9670180B2 (en) | 2012-01-25 | 2017-06-06 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| EP2807161B1 (en) | 2012-01-28 | 2017-10-04 | Merck Patent GmbH | Triazolo[4,5-d]pyrimidine derivatives |
| RS55388B1 (en) | 2012-02-09 | 2017-03-31 | Merck Patent Gmbh | FURO [3, 2 - B] PIRIDIN DERIVATIVES AS TBK1 AND IKK INHIBITORS |
| EP2812323B1 (en) | 2012-02-09 | 2016-04-06 | Merck Patent GmbH | Tetrahydro-quinazolinone derivatives as tank and parp inhibitors |
| EP2817310B1 (en) | 2012-02-21 | 2018-03-21 | Merck Patent GmbH | 8-substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors |
| CA2865040C (en) | 2012-02-21 | 2020-07-14 | Merck Patent Gmbh | Cyclic diaminopyrimidine derivatives |
| ES2606638T3 (en) | 2012-02-21 | 2017-03-24 | Merck Patent Gmbh | Furopyridine derivatives |
| CA2866450C (en) | 2012-03-07 | 2020-02-18 | Merck Patent Gmbh | Triazolopyrazine derivatives |
| WO2013144532A1 (en) | 2012-03-30 | 2013-10-03 | Astrazeneca Ab | 3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents |
| KR101674784B1 (en) | 2012-04-05 | 2016-11-09 | 에프. 호프만-라 로슈 아게 | Bispecific antibodies against human tweak and human il17 and uses thereof |
| EP2852285B1 (en) | 2012-04-29 | 2018-08-08 | Neupharma, Inc. | Bufadienolide compounds substituted in position 3 by a heterocyclic amine for use in the treatment of cancer |
| AU2013257018B2 (en) | 2012-05-04 | 2017-02-16 | Merck Patent Gmbh | Pyrrolotriazinone derivatives |
| GB201211021D0 (en) | 2012-06-21 | 2012-08-01 | Cancer Rec Tech Ltd | Pharmaceutically active compounds |
| WO2014015934A1 (en) | 2012-07-24 | 2014-01-30 | Merck Patent Gmbh | Hydroxystatin derivatives for treatment of arthrosis |
| CA2881279C (en) | 2012-08-07 | 2020-07-07 | Merck Patent Gmbh | Pyridopyrimidine derivatives as protein kinase inhibitors |
| AU2013301870B2 (en) | 2012-08-08 | 2017-04-27 | Merck Patent Gmbh | (Aza-)isoquinolinone derivatives |
| US20160009686A1 (en) | 2012-08-17 | 2016-01-14 | Cancer Therapeutics Crc Pty Limited | Vegfr3 inhibitors |
| CN102898330B (en) * | 2012-09-03 | 2015-02-25 | 浙江大学 | Colchicine Derivatives |
| WO2014041349A1 (en) | 2012-09-12 | 2014-03-20 | Cancer Therapeutics Crc Pty Ltd | Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors |
| WO2014045101A1 (en) | 2012-09-21 | 2014-03-27 | Cellzome Gmbh | Tetrazolo quinoxaline derivatives as tankyrase inhibitors |
| WO2014047648A1 (en) | 2012-09-24 | 2014-03-27 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| US9388142B2 (en) | 2012-09-26 | 2016-07-12 | Merck Patent Gmbh | Quinazolinone derivatives as PARP inhibitors |
| EP2911692B1 (en) | 2012-10-26 | 2019-08-21 | The University of Queensland | Use of endocytosis inhibitors and antibodies for cancer therapy |
| JP6304776B2 (en) | 2012-11-05 | 2018-04-04 | ジーエムディーエックス カンパニー プロプライエタリー リミテッド | Method for determining the cause of somatic mutagenesis |
| WO2014075077A1 (en) | 2012-11-12 | 2014-05-15 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| WO2014075754A1 (en) | 2012-11-16 | 2014-05-22 | Merck Patent Gmbh | 3-aminocyclopentane carboxamide derivatives |
| US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
| CN105246888B (en) | 2013-01-31 | 2017-09-05 | 尼奥迈德研究所 | Imidazopyridine compounds and uses thereof |
| CA2902080A1 (en) | 2013-02-25 | 2014-08-28 | Merck Patent Gmbh | 2-amino-3,4-dihydroquinazoline derivatives and the use thereof as cathepsin d inhibitors |
| EP2964648B1 (en) | 2013-03-05 | 2016-11-16 | Merck Patent GmbH | 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents |
| CN105142648A (en) | 2013-03-15 | 2015-12-09 | 玛格塞蒂克斯公司 | Magnesium compositions for cancer and uses thereof |
| WO2014144715A1 (en) | 2013-03-15 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | Hsp90-targeted cardiac imaging and therapy |
| AR095443A1 (en) | 2013-03-15 | 2015-10-14 | Fundación Centro Nac De Investig Oncológicas Carlos Iii | HEREROCICLES CONDENSED WITH ACTION ON ATR |
| WO2014161570A1 (en) | 2013-04-03 | 2014-10-09 | Roche Glycart Ag | Antibodies against human il17 and uses thereof |
| EP3004073A1 (en) | 2013-06-07 | 2016-04-13 | Université catholique de Louvain | 3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases |
| WO2014205511A1 (en) | 2013-06-25 | 2014-12-31 | University Of Canberra | Methods and compositions for modulating cancer stem cells |
| CN111285813A (en) | 2013-08-23 | 2020-06-16 | 润新生物公司 | Chemical entities, compositions and methods |
| ES2851724T3 (en) | 2013-09-18 | 2021-09-08 | Epiaxis Therapeutics Pty Ltd | Stem cell modulation |
| EP3052660A4 (en) | 2013-10-01 | 2017-04-26 | Queensland University Of Technology | Kits and methods for diagnosis, screening, treatment and disease monitoring |
| US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| EP3185858A4 (en) | 2014-08-25 | 2017-12-27 | University of Canberra | Compositions for modulating cancer stem cells and uses therefor |
| WO2016077881A1 (en) | 2014-11-17 | 2016-05-26 | The University Of Queensland | Glycoprotein biomarkers for esophageal adenocarcinoma and barrett's esophagus and uses thereof |
| MA41179A (en) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | PARG INHIBITOR COMPOUNDS |
| GB201501870D0 (en) | 2015-02-04 | 2015-03-18 | Cancer Rec Tech Ltd | Autotaxin inhibitors |
| GB201502020D0 (en) | 2015-02-06 | 2015-03-25 | Cancer Rec Tech Ltd | Autotaxin inhibitory compounds |
| CN107613769A (en) | 2015-02-17 | 2018-01-19 | 润新生物公司 | Certain chemical entities, compositions and methods |
| GB201510019D0 (en) | 2015-06-09 | 2015-07-22 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| EP3957637B1 (en) | 2015-08-04 | 2023-06-28 | Aucentra Therapeutics Pty Ltd | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds |
| US11419934B2 (en) | 2015-08-18 | 2022-08-23 | Oncotelic Therapeutics, Inc. | Use of VDAS to enhance immunomodulating therapies against tumors |
| JP6850294B2 (en) | 2015-08-26 | 2021-03-31 | ジーエムディーエックス カンパニー プロプライエタリー リミテッド | How to Detect Cancer Recurrence |
| KR20180095694A (en) | 2015-12-23 | 2018-08-27 | 퀸스랜드 유니버시티 오브 테크놀로지 | Nucleic acid oligomers and uses thereof |
| CN116082457A (en) | 2016-02-01 | 2023-05-09 | 堪培拉大学 | Protein compounds and uses thereof |
| CA3014674C (en) | 2016-02-15 | 2024-06-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods comprising fixed intermittent dosing of cediranib |
| HUE060082T2 (en) | 2016-04-15 | 2023-01-28 | Cancer Research Tech Ltd | Heterocyclic compounds as ret kinase inhibitors |
| GB2554333A (en) | 2016-04-26 | 2018-04-04 | Big Dna Ltd | Combination therapy |
| US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
| HUE059242T2 (en) | 2016-07-29 | 2022-11-28 | Rapt Therapeutics Inc | Azetidine derivatives as chemokine receptor modulators and their use |
| CA3033370A1 (en) | 2016-08-15 | 2018-02-22 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| ES2845048T3 (en) | 2016-09-22 | 2021-07-23 | Cancer Research Tech Ltd | Preparation and uses of pyrimidinone derivatives |
| GB201617103D0 (en) | 2016-10-07 | 2016-11-23 | Cancer Research Technology Limited | Compound |
| US10786502B2 (en) | 2016-12-05 | 2020-09-29 | Apros Therapeutics, Inc. | Substituted pyrimidines containing acidic groups as TLR7 modulators |
| BR112019011284A2 (en) | 2016-12-05 | 2019-10-22 | Apros Therapeutics, Inc | compound, pharmaceutical composition, methods of treating a condition, hbv and cancer, and, use of a compound. |
| JP7113528B2 (en) | 2017-02-01 | 2022-08-05 | オーセントラ セラピュティクス ピーティーワイ エルティーディー | N-Cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine derivatives as therapeutic agents |
| WO2018162625A1 (en) | 2017-03-09 | 2018-09-13 | Truly Translational Sweden Ab | Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease |
| GB201704325D0 (en) | 2017-03-17 | 2017-05-03 | Argonaut Therapeutics Ltd | Compounds |
| GB201705971D0 (en) | 2017-04-13 | 2017-05-31 | Cancer Res Tech Ltd | Inhibitor compounds |
| US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| CN108864079B (en) | 2017-05-15 | 2021-04-09 | 深圳福沃药业有限公司 | Triazine compound and pharmaceutically acceptable salt thereof |
| EP3630749B9 (en) | 2017-05-26 | 2024-05-29 | Cancer Research Technology Limited | 2-quinolone derived inhibitors of bcl6 |
| KR102828518B1 (en) | 2017-05-26 | 2025-07-04 | 캔써 리서치 테크놀로지 리미티드 | Benzimidazolone derived inhibitors of bcl6 |
| WO2018220101A1 (en) | 2017-05-31 | 2018-12-06 | Truly Translational Sweden Ab | A pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy |
| AU2017422200B2 (en) | 2017-07-05 | 2022-11-24 | E.P.O.S Iasis Research And Development Limited | Multifunctional conjugates |
| SG11202000823WA (en) | 2017-08-01 | 2020-02-27 | Merck Patent Gmbh | Thiazolopyridine derivatives as adenosine receptor antagonists |
| WO2019034890A1 (en) | 2017-08-18 | 2019-02-21 | Cancer Research Technology Limited | Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer |
| CA3073343A1 (en) | 2017-08-21 | 2019-02-28 | Merck Patent Gmbh | Quinoxaline derivatives as adenosine receptor antagonists |
| IL272637B2 (en) | 2017-08-21 | 2024-03-01 | Merck Patent Gmbh | Benzimidazole derivatives, their preparation and medicaments containing them |
| TWI702205B (en) | 2017-10-06 | 2020-08-21 | 俄羅斯聯邦商拜奧卡德聯合股份公司 | Epidermal growth factor receptor inhibitors |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| NL2019801B1 (en) | 2017-10-25 | 2019-05-02 | Univ Leiden | Delivery vectors |
| KR20200104291A (en) | 2017-11-06 | 2020-09-03 | 랩트 테라퓨틱스, 인크. | Anticancer drugs |
| EP3488868B1 (en) | 2017-11-23 | 2023-09-13 | medac Gesellschaft für klinische Spezialpräparate mbH | Pharmaceutical composition for oral administration containing sulfasalazine and / or a sulfasalazine organic salt, production process and use |
| EP3489222A1 (en) | 2017-11-23 | 2019-05-29 | medac Gesellschaft für klinische Spezialpräparate mbH | Sulfasalazine salts, production processes and uses |
| JP7406808B2 (en) | 2018-01-15 | 2023-12-28 | オーセントラ セラピュティクス ピーティーワイ エルティーディー | 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents |
| GB201801128D0 (en) | 2018-01-24 | 2018-03-07 | Univ Oxford Innovation Ltd | Compounds |
| RU2020128176A (en) | 2018-01-26 | 2022-03-02 | Рапт Терапьютикс, Инк. | CHEMOKINE RECEPTOR MODULATORS AND THEIR APPLICATIONS |
| CA3090528A1 (en) | 2018-02-08 | 2019-08-15 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| WO2019175093A1 (en) | 2018-03-12 | 2019-09-19 | Astrazeneca Ab | Method for treating lung cancer |
| KR20250105504A (en) | 2018-04-13 | 2025-07-08 | 캔써 리서치 테크놀로지 리미티드 | Bcl6 inhibitors |
| JP7427655B2 (en) | 2018-04-27 | 2024-02-05 | スプルース バイオサイエンシーズ,インク. | Methods for Treating Testicular Adrenal Residual Tumors and Ovarian Adrenal Residual Tumors |
| GB201809102D0 (en) | 2018-06-04 | 2018-07-18 | Univ Oxford Innovation Ltd | Compounds |
| CN112513031A (en) | 2018-06-04 | 2021-03-16 | 阿普罗斯治疗公司 | Acid group containing pyrimidine compounds useful for the treatment of diseases associated with the modulation of TLR7 |
| EP3802544A1 (en) | 2018-06-05 | 2021-04-14 | RAPT Therapeutics, Inc. | Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses |
| GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
| GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
| FI4360713T3 (en) | 2018-09-18 | 2024-12-27 | Hoffmann La Roche | Quinazoline derivatives as antitumor agents |
| WO2020068600A1 (en) | 2018-09-24 | 2020-04-02 | Rapt Therapeutics, Inc. | Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof |
| ES2960883T3 (en) | 2018-10-25 | 2024-03-07 | Merck Patent Gmbh | 5-azaindazole derivatives as adenosine receptor antagonists |
| JP7551607B2 (en) | 2018-10-25 | 2024-09-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 5-Azaindazole Derivatives as Adenosine Receptor Antagonists |
| GB201819126D0 (en) | 2018-11-23 | 2019-01-09 | Cancer Research Tech Ltd | Inhibitor compounds |
| CN114729354A (en) | 2018-12-25 | 2022-07-08 | 中国医学科学院基础医学研究所 | Small RNA drugs for prevention and treatment of inflammatory related diseases and their combinations |
| AR117844A1 (en) | 2019-01-22 | 2021-09-01 | Merck Patent Gmbh | THIAZOLOPYRIDINE DERIVATIVES AS ANTAGONISTS OF THE ADENOSINE RECEPTOR |
| JP7578602B2 (en) | 2019-02-25 | 2024-11-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー3)、リミテッド | Treatment with P2X3 modulators |
| US11033547B2 (en) | 2019-03-07 | 2021-06-15 | Merck Patent Gmbh | Carboxamide-pyrimidine derivatives as SHP2 antagonists |
| CA3130727A1 (en) | 2019-03-28 | 2020-10-01 | Amplia Therapeutics Limited | A salt and crystal form of a fak inhibitor |
| CN111747950B (en) | 2019-03-29 | 2024-01-23 | 深圳福沃药业有限公司 | Pyrimidine derivatives for the treatment of cancer |
| MX2021011810A (en) | 2019-03-29 | 2021-10-26 | Astrazeneca Ab | Osimertinib for use in the treatment of non-small cell lung cancer. |
| EP3946618A1 (en) | 2019-04-05 | 2022-02-09 | Storm Therapeutics Ltd | Mettl3 inhibitory compounds |
| CA3127475A1 (en) | 2019-04-08 | 2020-10-15 | Merck Patent Gmbh | Pyrimidinone derivatives as shp2 antagonists |
| GB201905328D0 (en) | 2019-04-15 | 2019-05-29 | Azeria Therapeutics Ltd | Inhibitor compounds |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| GB201908885D0 (en) | 2019-06-20 | 2019-08-07 | Storm Therapeutics Ltd | Therapeutic compounds |
| CN114728910B (en) | 2019-08-31 | 2024-05-14 | 上海奕拓医药科技有限责任公司 | Pyrazole derivatives for FGFR inhibitors and preparation methods thereof |
| TWI873187B (en) | 2019-09-20 | 2025-02-21 | 美商愛德亞生物科學公司 | 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors |
| GB201913988D0 (en) | 2019-09-27 | 2019-11-13 | Celleron Therapeutics Ltd | Novel treatment |
| GB201914860D0 (en) | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
| GB201915831D0 (en) | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
| GB201915829D0 (en) | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
| GB201915828D0 (en) | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
| AU2020394867A1 (en) | 2019-12-02 | 2022-05-26 | Storm Therapeutics Limited | Polyheterocyclic compounds as METTL3 inhibitors |
| GB202004960D0 (en) | 2020-04-03 | 2020-05-20 | Kinsenus Ltd | Inhibitor compounds |
| US20230183197A1 (en) | 2020-06-01 | 2023-06-15 | Neophore Limited | Inhibitors of mlh1 and/or pms2 for cancer treatment |
| GB202012482D0 (en) | 2020-08-11 | 2020-09-23 | Univ Of Huddersfield | Novel compounds and therapeutic uses thereof |
| GB202012969D0 (en) | 2020-08-19 | 2020-09-30 | Univ Of Oxford | Inhibitor compounds |
| WO2022074379A1 (en) | 2020-10-06 | 2022-04-14 | Storm Therapeutics Limited | Mettl3 inhibitory compounds |
| US20240101589A1 (en) | 2020-10-08 | 2024-03-28 | Strom Therapeutics Limited | Inhibitors of mettl3 |
| WO2022182415A1 (en) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
| GB202102895D0 (en) | 2021-03-01 | 2021-04-14 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| WO2022197641A1 (en) | 2021-03-15 | 2022-09-22 | Rapt Therapeutics, Inc. | 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases |
| CA3218697A1 (en) | 2021-05-03 | 2022-11-10 | Merck Patent Gmbh | Her2 targeting fc antigen binding fragment-drug conjugates |
| JP2024519054A (en) | 2021-05-17 | 2024-05-08 | エイチケイ イノ.エヌ コーポレーション | BENZAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF CANCER - Patent application |
| CN117999101A (en) | 2021-05-25 | 2024-05-07 | 默克专利股份公司 | Fc antigen-binding fragment-drug conjugate targeting EGFR |
| GB202107907D0 (en) | 2021-06-02 | 2021-07-14 | Storm Therapeutics Ltd | Combination therapies |
| GB202108383D0 (en) | 2021-06-11 | 2021-07-28 | Argonaut Therapeutics Ltd | Compounds useful in the treatment or prevention of a prmt5-mediated disorder |
| GB202110373D0 (en) | 2021-07-19 | 2021-09-01 | Neophore Ltd | Inhibitor compounds |
| IT202100023357A1 (en) | 2021-09-09 | 2023-03-09 | Cheirontech S R L | Peptides with anti-angiogenic activity |
| US20250002491A1 (en) | 2021-10-04 | 2025-01-02 | Forx Therapeutics Ag | N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer |
| AU2022359801A1 (en) | 2021-10-04 | 2024-02-01 | Forx Therapeutics Ag | Parg inhibitory compounds |
| GB202117224D0 (en) | 2021-11-29 | 2022-01-12 | Neophore Ltd | Inhibitor compounds |
| GB202117225D0 (en) | 2021-11-29 | 2022-01-12 | Neophore Ltd | Protac compounds |
| CN119421877A (en) | 2022-01-10 | 2025-02-11 | 默克专利股份公司 | Substituted heterocyclic compounds as HSET inhibitors |
| GB202202006D0 (en) | 2022-02-15 | 2022-03-30 | Chancellor Masters And Scholars Of The Univ Of Oxford | Anti-cancer treatment |
| GB202202199D0 (en) | 2022-02-18 | 2022-04-06 | Cancer Research Tech Ltd | Compounds |
| WO2023175184A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| WO2023175185A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| GB202204935D0 (en) | 2022-04-04 | 2022-05-18 | Cambridge Entpr Ltd | Nanoparticles |
| WO2023196432A1 (en) | 2022-04-06 | 2023-10-12 | Rapt Therapeutics, Inc. | Chemokine receptor modulators and uses thereof |
| EP4522597A1 (en) | 2022-05-11 | 2025-03-19 | Cancer Research Technology Limited | Ikk inhibitors |
| GB202209404D0 (en) | 2022-06-27 | 2022-08-10 | Univ Of Sussex | Compounds |
| WO2024030825A1 (en) | 2022-08-01 | 2024-02-08 | Neupharma, Inc | Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate |
| GB202213166D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| GB202213167D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| GB202213162D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Prodrugs |
| GB202213164D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| GB202213163D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| WO2024074497A1 (en) | 2022-10-03 | 2024-04-11 | Forx Therapeutics Ag | Parg inhibitory compound |
| WO2024094963A1 (en) | 2022-11-02 | 2024-05-10 | Cancer Research Technology Limited | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer |
| WO2024094962A1 (en) | 2022-11-02 | 2024-05-10 | Cancer Research Technology Limited | Pyrido[2,3-d]pyrimidin-2-amine derivatives as egfr inhibitors for the treatment of cancer |
| AR130957A1 (en) | 2022-11-07 | 2025-02-05 | Merck Patent Gmbh | SUBSTITUTED BICYCLIC AND TRICYCLIC HSET INHIBITORS |
| GB202218672D0 (en) | 2022-12-12 | 2023-01-25 | Storm Therapeutics Ltd | Inhibitory compounds |
| GB202300881D0 (en) | 2023-01-20 | 2023-03-08 | Neophore Ltd | Inhibitor compounds |
| WO2024173514A1 (en) | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Amide and ester-substituted imidazopyridine compounds |
| WO2024173530A1 (en) | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted pyrazolo/imidazo pyridine compounds |
| WO2024173453A1 (en) | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted imidazopyridine compounds |
| WO2024173524A1 (en) | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted benzimidazole compounds |
| US12145945B2 (en) | 2023-03-10 | 2024-11-19 | Breakpoint Therapeutics Gmbh | Compounds, compositions, and therapeutic uses thereof |
| EP4688159A1 (en) | 2023-04-05 | 2026-02-11 | FoRx Therapeutics AG | Parg inhibitory compounds |
| GB202306601D0 (en) | 2023-05-04 | 2023-06-21 | Cancer Research Tech Ltd | Inhibitor compounds |
| GB202307924D0 (en) | 2023-05-26 | 2023-07-12 | Neophore Ltd | Inhibitor compounds |
| GB2631509A (en) | 2023-07-04 | 2025-01-08 | Univ Liverpool | Compositions |
| GB2631507A (en) | 2023-07-04 | 2025-01-08 | Univ Liverpool | Compositions |
| WO2025046148A1 (en) | 2023-09-01 | 2025-03-06 | Forx Therapeutics Ag | Novel parg inhibitors |
| WO2025056923A1 (en) | 2023-09-15 | 2025-03-20 | Cambridge Enterprise Limited | Combination therapy |
| WO2025073792A1 (en) | 2023-10-02 | 2025-04-10 | Forx Therapeutics Ag | Wrn inhibitory compounds |
| WO2025073870A1 (en) | 2023-10-03 | 2025-04-10 | Forx Therapeutics Ag | Parg inhibitory compound |
| GB202315149D0 (en) | 2023-10-03 | 2023-11-15 | Celleron Therapeutics Ltd | Combination therapy |
| GB202316595D0 (en) | 2023-10-30 | 2023-12-13 | Storm Therapeutics Ltd | Inhibitory compounds |
| GB202316683D0 (en) | 2023-10-31 | 2023-12-13 | Storm Therapeutics Ltd | Inhibitory compounds |
| WO2025093755A1 (en) | 2023-11-01 | 2025-05-08 | Forx Therapeutics Ag | Novel parc inhibitors |
| GB202317368D0 (en) | 2023-11-13 | 2023-12-27 | Breakpoint Therapeutics Gmbh | Novel compounds, compositions and therapeutic uses thereof |
| WO2025104443A1 (en) | 2023-11-14 | 2025-05-22 | Storm Therapeutics Ltd | Inhibitory compounds |
| WO2025114480A1 (en) | 2023-11-28 | 2025-06-05 | Forx Therapeutics Ag | Wrn inhibitory compounds |
| WO2025136811A1 (en) | 2023-12-18 | 2025-06-26 | Ideaya Biosciences, Inc. | Chemical compounds and uses thereof |
| GB202319863D0 (en) | 2023-12-21 | 2024-02-07 | Breakpoint Therapeutics Gmbh | Movel compounds, compositions and therapeutics uses thereof |
| GB202319864D0 (en) | 2023-12-21 | 2024-02-07 | Breakpoint Therapeutics Gmbh | Novel compounds, compositions and therapeutic uses thereof |
| WO2025133395A1 (en) | 2023-12-22 | 2025-06-26 | Forx Therapeutics Ag | Bicyclic (hetero)arylene wrn inhibitory compounds |
| WO2025133396A1 (en) | 2023-12-22 | 2025-06-26 | Forx Therapeutics Ag | Novel bicyclo heteroaryl parg inhibitors |
| WO2025191176A1 (en) | 2024-03-14 | 2025-09-18 | Forx Therapeutics Ag | Wrn inhibitory compounds |
| NL2037411B1 (en) | 2024-04-08 | 2025-10-31 | Univ Leiden | Protac compounds |
| GB202407738D0 (en) | 2024-05-31 | 2024-07-17 | Storm Therapeutics Ltd | Inhibitory compounds |
| WO2025262192A1 (en) | 2024-06-21 | 2025-12-26 | Breakpoint Therapeutics Gmbh | Quinazoline derivatives suitable for use as werner syndrome helicase protein inhibitors |
| WO2026003380A1 (en) | 2024-06-28 | 2026-01-02 | Forx Therapeutics Ag | Wrn inhibitory compounds |
| WO2026022150A1 (en) | 2024-07-22 | 2026-01-29 | Forx Therapeutics Ag | Parg inhibitory compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3442953A (en) * | 1963-06-19 | 1969-05-06 | Roussel Uclaf | Novel 7-oxo-7-desacetylaminocolchicine compounds |
| IT1270124B (en) | 1994-10-05 | 1997-04-28 | Indena Spa | COLCHICINE DERIVATIVES AND THEIR THERAPEUTIC USE |
| US5561122A (en) | 1994-12-22 | 1996-10-01 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Combretastatin A-4 prodrug |
| IT1276996B1 (en) | 1995-06-27 | 1997-11-04 | Indena Spa | COLCHICINE DERIVATIVES, THEIR USE AND FORMULATIONS CONTAINING THEM |
| US5760092A (en) | 1995-09-13 | 1998-06-02 | Brandeis University | Allocolchinones and uses thereof |
| IT1283110B1 (en) * | 1996-06-07 | 1998-04-07 | Indena Spa | COLCHYCINE SKELETON COMPOUNDS, THEIR USE AS DRUGS AND COMPOSITIONS THAT CONTAIN THEM |
| IT1291550B1 (en) * | 1997-04-11 | 1999-01-11 | Indena Spa | DERIVATIVES OF COLCHICINE AND THIOCOLCHICINE WITH ANTI-INFLAMMATORY AND MYORELAXING ACTIVITIES |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| JP2002537262A (en) | 1999-02-18 | 2002-11-05 | オキシジェン,インコーポレイティド | Compositions and methods for use in targeting vascular disruption |
-
1997
- 1997-07-08 GB GBGB9714249.1A patent/GB9714249D0/en active Pending
-
1998
- 1998-06-07 UA UA2000020626A patent/UA72731C2/en unknown
- 1998-07-06 IL IL13389998A patent/IL133899A0/en unknown
- 1998-07-06 CN CNB988069466A patent/CN1181825C/en not_active Expired - Fee Related
- 1998-07-06 SK SK13-2000A patent/SK132000A3/en unknown
- 1998-07-06 DE DE69835434T patent/DE69835434T2/en not_active Expired - Fee Related
- 1998-07-06 AU AU82311/98A patent/AU741213B2/en not_active Ceased
- 1998-07-06 KR KR1020007000094A patent/KR100655808B1/en not_active Expired - Fee Related
- 1998-07-06 BR BR9810681-3A patent/BR9810681A/en not_active IP Right Cessation
- 1998-07-06 US US09/477,805 patent/US6423753B1/en not_active Expired - Fee Related
- 1998-07-06 AT AT98932374T patent/ATE334684T1/en not_active IP Right Cessation
- 1998-07-06 EP EP98932374A patent/EP1001785B1/en not_active Expired - Lifetime
- 1998-07-06 WO PCT/GB1998/001977 patent/WO1999002166A1/en not_active Ceased
- 1998-07-06 NZ NZ501341A patent/NZ501341A/en unknown
- 1998-07-06 RU RU2000102889/15A patent/RU2232021C2/en not_active IP Right Cessation
- 1998-07-06 CA CA002292549A patent/CA2292549C/en not_active Expired - Fee Related
- 1998-07-06 TR TR1999/03149T patent/TR199903149T2/en unknown
- 1998-07-06 ID IDW20000023A patent/ID25483A/en unknown
- 1998-07-06 JP JP50831399A patent/JP3455549B2/en not_active Expired - Fee Related
- 1998-07-06 ES ES98932374T patent/ES2270524T3/en not_active Expired - Lifetime
- 1998-07-06 CZ CZ200018A patent/CZ296018B6/en not_active IP Right Cessation
- 1998-07-06 HU HU0002493A patent/HUP0002493A3/en unknown
- 1998-07-06 PL PL98337926A patent/PL337926A1/en unknown
-
2000
- 2000-01-07 NO NO20000077A patent/NO321621B1/en not_active IP Right Cessation
-
2006
- 2006-03-01 NO NO20061016A patent/NO20061016L/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2000102889A (en) | APPLICATION OF KOLKHINOL DERIVATIVES AS A MEANS DAMAGING VESSELS | |
| EP2067784A3 (en) | 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivatives as anti-inflammatory agents | |
| RU2088589C1 (en) | Derivatives of 17 beta-substituted-4-aza-5-5 alpha-androstane-3-ones, methods of synthesis of compounds, pharmaceutical composition, compound 4 | |
| WO2003035668A3 (en) | Novel anti-inflammatory androstane derivatives -17-carboxy-lactone substituted steroids with an aryl-carboxylic ester in position 17.alpha | |
| IL133623A0 (en) | Antithrombotic agents | |
| IL133627A0 (en) | Antithrombotic agents | |
| CA2161542A1 (en) | Novel 5-Pyrrolyl-2-Pyridylmethylsulfinyl Benzimidazole Derivatives | |
| AU7517400A (en) | N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent | |
| DE69221563D1 (en) | Polyfluoroalkylthiopoly (ethylimidazolium) compounds, process for their preparation and their use as biocidal agents | |
| ATE83773T1 (en) | 3(2H)PYRIDAZINONE, PROCESS FOR ITS PREPARATION AND ANTI-SRS-A AGENT CONTAINING IT. | |
| AU6652390A (en) | Compositions and their use in lowering intraocular pressure | |
| RU2003134629A (en) | CEPHEMA COMPOUNDS | |
| AR036176A1 (en) | A PHENYL-ACETAMID-TIAZOL DERIVATIVE, A PROCEDURE FOR PREPARATION, A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, A PRODUCT OR KIT THAT UNDERSTANDS THEM, AND A METHOD THAT USES SUCH DERIVATIVE | |
| DE59208058D1 (en) | New tetrazole derivatives, processes for their preparation and their use | |
| DE69330601D1 (en) | SEROTON INERGIC ERGOLIN DERIVATIVES | |
| IL112432A0 (en) | Fatty acid derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same | |
| DE3868013D1 (en) | THIAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT. | |
| NZ504706A (en) | Substituted isoquinoline derivatives and their use as anticonvulsants | |
| DE59800034D1 (en) | 11 beta-benzaldoxim-9 alpha, 10 alpha-epoxy-estr-4-ene derivatives, process for their preparation and pharmaceutical preparations containing these compounds | |
| DE60020130D1 (en) | PROCESS FOR THE PREPARATION OF 3-AMINO-GALLENSAUR DERIVATIVES | |
| PL334088A1 (en) | Novel derivatives of n-benzenesulphonyl-l-proline, methods of obtaining them and pharmaceutic agents | |
| AU1076802A (en) | Selective glucocorticoid receptor agonists | |
| BR0112957A (en) | Compound, method of treatment, use of a compound, and pharmaceutical composition | |
| AR046212A1 (en) | DERIVATIVES OF 2-PHENYLBENZOFURANE, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| DE3671016D1 (en) | THIAZOLIDE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF. |